Detection Method:Sandwich
Test principle:This assay employs a two-site sandwich ELISA to quantitate DLC1 in samples. An antibody specific for DLC1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyDLC1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for DLC1 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of DLC1 bound in the initial step. The color development is stopped and the intensity of the color is measured.
Product Overview:Deleted in Liver Cancer 1 is deleted in the primary tumor of hepatocellular carcinoma. It maps to 8p22-p21.3, a region frequently deleted in solid tumors. It is suggested that this gene is a candidate tumor suppressor gene for human liver cancer, as well as for prostate, lung, colorectal, and breast cancers.DLC1 is frequently inactivated in human hepatocellular carcinoma, as well as some nasopharyngeal, lung, breast, prostate, kidney, colon, uterine, ovarian, and gastric cancers.
The DLC1 protein contains four major functional domains: an N-terminal sterile α motif (SAM), a serine-rich (SR) region, a Rho-GAP domain, and a C-terminal steroidogenic acute regulatory protein related lipid-transfer (START) domain. DLC1 is localized to focal adhesions located at the periphery of cells.
